Abstract

The human microbiome plays a critical role in drug metabolism, influencing both pharmacokinetics and 
pharmacodynamics, with significant implications for therapeutic efficacy and safety. Microorganisms in the gut, 
including bacteria, archaea, fungi, and viruses, contribute to the activation, inactivation, detoxification, or 
reactivation of drugs, often determining interindividual variability in treatment outcomes. Microbial metabolites 
regulate host metabolic pathways, alter immune responses, and modulate drug absorption and distribution, 
thereby impacting drug efficacy and the risk of adverse drug reactions (ADRs). Factors such as diet, antibiotic use, 
lifestyle, and environmental influences shape the microbiome’s composition, making it a key determinant of 
patient-specific drug responses. Advances in sequencing technologies, metabolomics, and in vitro modeling have 
improved understanding of microbiome–drug interactions, paving the way for novel therapeutic strategies, 
microbiome modulation, and personalized medicine. However, clinical translation faces challenges, including 
ethical considerations, regulatory barriers, and the need for standardized microbiome profiling in clinical trials. 
Addressing these challenges is essential for optimizing pharmacological treatment, minimizing ADRs, and 
advancing the integration of microbiome science into precision medicine. 
Keywords: Microbiome, Drug Metabolism, Pharmacokinetics, Adverse Drug Reactions, and Personalized 
Medicine